entacapone and Dyspnea

Pergolide, an ergot-derived dopamine agonist prescribed since the late 1980's mainly in Parkinson's disease and restless leg syndrome has recognized fibrosis side effects, affecting the pleural, pericardial and retroperitoneal systems. Pergolide-induced valvulopathies were first reported in 2002. We present here the history of a patient developing an isolated pulmonary hypertension related to the intake of pergolide. The dyspnea related to the pulmonary hypertension as well as the echocardiographic abnormalities improved after treatment replacement. Valvulopathies and pulmonary hypertension were previously described under appetite-suppressant drugs after years of clinical use, in a similar way.

Topics: Antiparkinson Agents; Benserazide; Benzothiazoles; Blood Pressure; Catechols; Dyspnea; Echocardiography; Humans; Hypertension, Pulmonary; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease, Postencephalitic; Pergolide; Pramipexole